

Our ref: IG/FOI/FOI.121.24

4 December 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 22 November 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) partly holds the information that you require. For ease of reference your request is set out below and my response follows.

Your Freedom of Information (FOI) Request:

I am writing to make a formal request for information under the provisions of the Freedom of Information Act (FOIA). I am seeking answers to the following questions:

Q1. How many patients were treated in the last 6-month period with Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate for HIV treatment?

Q2. How many patients were treated in the last 6-month period with Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate for Pre-exposure prophylaxis (PrEP)?

Q3. How many packs of Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for HIV treatment?

Q4. How many packs of Truvada (emtricitabine / tenofovir disoproxil fumarate) or generic emtricitabine / tenofovir disoproxil fumarate were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?

Q5. How many patients were treated in the last 6-month period with Descovy (tenofovir alafenamide / emtricitabine) for HIV treatment?

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661



Q6. How many patients were treated in the last 6-month period with Descovy (tenofovir alafenamide / emtricitabine) for Pre-exposure prophylaxis (PrEP)?

Q7. How many packs of Descovy (tenofovir alafenamide / emtricitabine) were dispensed in latest 6-month period for HIV treatment?

Q8. How many packs of Descovy (tenofovir alafenamide / emtricitabine) were dispensed in latest 6-month period for Pre-exposure prophylaxis (PrEP)?

Powys Response:

Please see the following link for 'appraisal in progress' for use of Descovy in Pre-exposure prophylaxis (PrEP) in Wales: [emtricitabine/tenofovir alafenamide fumarate \(Descovy®\) - All Wales Therapeutics and Toxicology Centre](#)

Q1, 3, 5 & 7. Powys Teaching Health Board (PTHB) does not directly provide Human Immunodeficiency Virus (HIV) treatments, patients are referred to providers outside Powys. Any patients requiring HIV treatment would be referred to and treated by specialist providers outside Powys. We therefore recommend that you approach them directly for this information via the details below:

Health Trust/ Organisation	FOI Contact Details
Midlands Partnership University Foundation Trust	FOI@mpft.nhs.uk
Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk

Q2, Q4, Q6 & Q8. I can confirm that PTHB has not provided any PrEP medication to patients in the last 6 months. This is a service we are currently working towards providing.

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via powysfoi.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Richard Stratton
Assistant Medical Director-Primary Care

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.